Intuitive Surgical, the pioneer of robotic-assisted surgery, used the Society of Robotic Surgery (SRS) 2026 annual meeting in Hollywood, Florida to outline a long-term vision for AI in surgery. The company, disclosed in a GlobeNewswire release on July 23, 2026, said its roadmap spans intraoperative AI on the da Vinci 5 platform, expanded SimNow training environments and a growing developer program that opens Intuitive data streams to third-party AI builders.
What Intuitive Is Building
Chief Scientific Officer Jonathan Sorger's SRS remarks emphasized "AI that helps in every phase of care" — pre-op planning, intraoperative decision support, post-op analytics and workforce training. Intuitive highlighted case-guidance features already shipping on da Vinci 5 as part of its 100-update wave, expanded telepresence and telesimulation, and a broader push to make surgical AI a systems-level capability rather than a single feature.
Competitive Stakes
The vision statement lands the same week Medtronic unveiled its Touch Surgery Aide AI compute platform and days after Intuitive reported $2.89 billion in Q2 revenue with 468 da Vinci placements. Intuitive still leads the market by a wide margin, but SRS 2026 is turning into an AI arms race, with CMR Surgical and other entrants also updating their software roadmaps.
Data As The Moat
Analysts note that Intuitive's real advantage is data: it collects more procedure-level signal than any competitor, and its AI story at SRS 2026 leans on that scale — using anonymized surgical video, sensor and outcome data to train and validate models for skill assessment, case coaching and workflow automation. Opening curated APIs to hospital partners and startups extends that flywheel.
For customers, the message is that da Vinci is being repositioned as an intelligent surgical platform rather than a robotic instrument alone — a shift that will reshape how hospitals evaluate, buy and finance robotic surgery over the next several years.
Reporting based on coverage from Intuitive Surgical, GlobeNewswire, Modern Healthcare and Duke Research.